Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel

被引:16
作者
Minami, H
Sasaki, Y
Watanabe, T
Ogawa, M
机构
[1] Natl Canc Ctr Hosp E, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr, Chuo Ku, Tokyo 1040045, Japan
[3] Aichi Canc Ctr, Chikusa Ku, Nagoya, Aichi 4640021, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 2001年 / 92卷 / 02期
关键词
pharmacokinetics; pharmacodynamics; leukopenia; fever; chemotherapy;
D O I
10.1111/j.1349-7006.2001.tb01086.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The entire time course of leukopenia after anticancer treatment is clinically more relevant than a singly measured nadir count. In order to identify factors associated with neutropenic fever, a mechanistic pharmacodynamic model with two compartments corresponding to leukocytes in bone marrow and peripheral blood was applied to describe the time course of leukopenia, seventeen patients with breast cancer were treated with 210 mg/m(2) of paclitaxel infused over 3 h as a single agent in a phase II. study, Adequate fitting of the time course of leukopenia was achieved in all patients, and time-dependent parameters, including the time period during which leukocyte counts remained below 2000/mu1 and the area between the curve for time versus leukocyte counts and the line of a leukocyte count of 2000/mul (A<2000), were calculated in each patient. Leukopenia was not significantly correlated with pharmacokinetic parameters, including time above a threshold concentration or the area under the time-concentration curve. A negative correlation between age and the sensitivity parameter of the pharmacodynamic model was observed (r(2)=0.21, P=0.07), Patients who experienced neutropenic fever had a larger A<2000 than patients who did not experience fever (4512 vs. 6 days/mul, P=0.05), but fever was not significantly related to any pharmacokinetic parameter or the leukocyte nadir count. Febrile episodes were better associated with the time course of leukopenia than the singly measured nadir count, and the pharmacodynamic model presents a novel platform to analyze the entire time course of leukopenia.
引用
收藏
页码:231 / 238
页数:8
相关论文
共 30 条
[1]  
ATHENS JW, 1993, CLIN HEMATOLOGY, V1, P239
[2]   QUANTITATIVE RELATIONSHIPS BETWEEN CIRCULATING LEUKOCYTES AND INFECTION IN PATIENTS WITH ACUTE LEUKEMIA [J].
BODEY, GP ;
BUCKLEY, M ;
SATHE, YS ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1966, 64 (02) :328-+
[3]   GRANULOCYTOPOIESIS IN HUMAN BONE MARROW CULTURES STUDIED BY MEANS OF KINEMATOGRAPHY [J].
BOLL, I ;
KUHN, A .
BLOOD-THE JOURNAL OF HEMATOLOGY, 1965, 26 (04) :449-&
[4]   Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer [J].
Bruno, R ;
Hille, D ;
Riva, A ;
Vivier, N ;
Huinnink, WWTB ;
van Oosterom, AT ;
Kaye, SB ;
Verweij, J ;
Fossella, FV ;
Valero, V ;
Rigas, JR ;
Seidman, AD ;
Chevallier, B ;
Fumoleau, P ;
Burris, HA ;
Ravclin, PM ;
Sheiner, LB .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :187-196
[5]   THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN [J].
CARTWRIGHT, GE ;
ATHENS, JW ;
WINTROBE, MM .
BLOOD, 1964, 24 (06) :780-803
[6]  
EXTRA JM, 1993, CANCER RES, V53, P1037
[7]  
FLIEDNER T. M., 1964, BLOOD J HEMATOL, V24, P683
[8]   NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS [J].
GIANNI, L ;
KEARNS, CM ;
GIANI, A ;
CAPRI, G ;
VIGANO, L ;
LOCATELLI, A ;
BONADONNA, G ;
EGORIN, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :180-190
[9]   PHARMACOKINETICS OF PACLITAXEL AND METABOLITES IN A RANDOMIZED COMPARATIVE-STUDY IN PLATINUM-PRETREATED OVARIAN-CANCER PATIENTS [J].
HUIZING, MT ;
KEUNG, ACF ;
ROSING, H ;
VANDERKUIJ, V ;
HUININK, WWT ;
MANDJES, IM ;
DUBBELMAN, AC ;
PINEDO, HM ;
BEIJNEN, JH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2127-2135
[10]   Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan [J].
Ito, Y ;
Horikoshi, N ;
Watanabe, T ;
Sasaki, Y ;
Tominaga, T ;
Okawa, T ;
Tabei, T ;
Kuraishi, Y ;
Tamura, K ;
Abe, R ;
Kitajima, M ;
Yamaguchi, S ;
Kobayashi, T ;
Koyama, H ;
Orita, K ;
Takashima, S ;
Nomura, Y ;
Ogawa, M .
INVESTIGATIONAL NEW DRUGS, 1998, 16 (02) :183-190